Gapping down
Other news:
- ALDX -38.3% (announced top-line results from Phase 3 TRANQUILITY trial in dry eye disease; primary endpoint of ocular redness was not met)
- AQST -28.1% (receives notification from FDA that it will not be ready to take action by December 23, 2021 for the Company's NDA for Libervant Buccal Film)
- DBVT -19.3% (announced plans to initiate new Phase 3 clinical study for modified Viaskin Peanut patch and to withdraw the MAA for Viaskin Peanut in Europe)
- CTMX -17.2% (announced preliminary results from Phase 2 expansion study of CX-2029 in patients with sqNSCLC or HNSCC)
- MNMD -6.7% (provides status update on IND for phase 2b Trial of LSD for the treatment of generalized anxiety disorder)
- ACAD -5.5% (announced plans to resubmit sNDA for NUPLAZID),
Analyst comments:
- VIR -4% (downgraded to Underperform from Neutral at Robert W. Baird)
- URI -1.2% (downgraded to Neutral from Outperform at Robert W. Baird),
Gapping up
In reaction to strong earnings/guidance:
- MU +8.8%, RAD +4%, NKE +3.6%,
Other news:
- IMV +8.6% (announces finalization of the basket clinical study in collaboration with Merck (MRK) and reveals promising top line data from the bladder and MSI-High Cohorts)
- TMST +3.2% (authorizes share repurchase program for up to $50 mln of common stock; Board of Directors also approves 2022 capital expenditure budget for $40 mln)
- FTAI +2.7% (submitted documentation with respect to potential spin-off of infrastructure business)
- NKLA +2.6% (confirms settlement agreement with SEC)
- PROG +2.5% (completes exit from laboratory business through asset sale to Northwest Pathology)
- FSR +2% (partners with Bridgestone (BRDCY) for comprehensive after-sales and related maintenance solutions in France and Germany)
- HAYW +1.6% (approved new $450 mln stock repurchase program)
- LLY +1.5% (lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in third Phase 3 study)
- SNY +1.1% (to acquire Amunix immuno-oncology pipeline with next generation Conditionally Activated Biologics)
- BA +1% (awarded $330 mln Air Force contract)
- NVS +1% (Sandoz submits Biologics License Application for proposed biosimilar trastuzumab to US FDA)
Analyst comments:
- PTEN +5.3% (upgraded to Overweight from Neutral at Piper Sandler)
- WEJO +5.3% (initiated with an Outperform at Wedbush)
- MKFG +5.2% (initiated with a Buy at Goldman)
- KLAC +4.4% (upgraded to Overweight from Equal Weight at Wells Fargo)
- VUZI +3.6% ( initiated with a Buy at Dawson James)
- HIPO +2.6% (initiated with an Overweight at Morgan Stanley)
- RMD +1.2% (upgraded to Overweight from Sector Weight at KeyBanc),
>>> Up
* Deutsche Boerse Raised to Buy at UBS; PT 165 euros
* ISS Raised to Buy at Handelsbanken; PT 145 kroner
* Neste Raised to Buy at Kepler Cheuvreux; PT 55 euros (+)
* Reckitt PT Raised to 9,400 pence from 8,900 pence at Barclays (+)
* Richemont Raised to Buy at Bryan Garnier; PT 140 Swiss francs (+)
* Straumann Raised to Outperform at Bernstein
>>> Down
* Straumann Raised to Outperform at Bernstein
>>> Down
* Alibaba ADRs Cut to Neutral at Atlantic Equities; PT $140 (+)
* BillerudKorsnas Cut to Hold at ABG; PT 175 kronor
>>> Initiation
* BillerudKorsnas Cut to Hold at ABG; PT 175 kronor
>>> Initiation
* Kalera Rated New Buy at Roth Capital; PT 15 kroner
* Nordex Rated New Buy at Stifel; PT 20 euros
* Petrofac Coverage Dropped by Morgan Stanley
* Petrofac Coverage Dropped by Morgan Stanley
* Roche Resumed Buy at Citi; PT 422 Swiss francs (+)
* Skan Group Rated New Neutral at Credit Suisse (+)
>>> Call
>>> Call
* Deutsche Boerse Upgraded at UBS as Cyclical Headwinds Abate
* TUI New Hold at Peel Hunt, Recovery Potential With Uncertainties
* TUI New Hold at Peel Hunt, Recovery Potential With Uncertainties
DAX:
- HelloFresh (HFG TH) +2.3%
- Adidas (ADS TH) +2.3%
- Watch European Sportswear Stocks as Nike Rises After 2Q Report
- Deutsche Boerse (DB1 TH) +2.1%
- Deutsche Boerse Upgraded at UBS as Cyclical Headwinds Abate
- Infineon (IFX TH) +1.9%
- Watch European Chipmaker Stocks After Micron’s Upbeat Forecast
- Siemens (SIE TH) +1.7%
MDAX:
- Aixtron (AIXA TH) +2.5%
- Watch European Chipmaker Stocks After Micron’s Upbeat Forecast
- Uniper (UN01 TH) +1.6%
- Aroundtown (AT1 TH) +1.4%
- Commerzbank (CBK TH) +1.3%
- Fraport (FRA TH) +1.1%
SDAX:
- Nordex (NDX1 TH) +3%
- Nordex Rated New Buy at Stifel; PT 20 euros
- Encavis (ECV TH) +2.5%
- Kloeckner (KCO TH) +2.5%
- LPKF (LPK TH) +1.5%
- STO SE & Co KGaA (STO3 TH) +1.4%
- Adler Group (ADJ TH) -1.4%
- Deutsche Boerse (DB1 TH) +2.2%
- Deutsche Boerse Upgraded at UBS as Cyclical Headwinds Abate
- Adidas (ADS TH) +2.1%
- Watch European Sportswear Stocks as Nike Rises After 2Q Report
- ASML (ASME TH) +2%
- Imperial Brands (ITB TH) +2%
- Airbus (AIR TH) +1.9%
- HelloFresh (HFG TH) +1.9%
- ArcelorMittal (ARRD TH) +1.9%
- Infineon (IFX TH) +1.8%
- Watch European Chipmaker Stocks After Micron’s Upbeat Forecast
- Novo Nordisk (NOVC TH) +1.8%
- Investor AB (IVSD TH) -0.5%
- Salmar (JEP TH) -0.8%
- Telefonica (TNE5 TH) -0.9%
- A2A (EAM TH) -1.3%
Turkey’s lira continued its rally at a strong pace, adding to Monday’s 23% surge that followed the announcement of extraordinary measures from the government to bolster the currency.
The lira soared as much as 20% against the U.S. dollar, extending the currency’s gains since Friday to more than 40%. The whipsaw trading saw the currency swing from a record low of 18.3633 early on Monday to as strong as 11.0990 in Istanbul on Tuesday morning. The two-day rally is the biggest since 1983, according to data compiled by Bloomberg.
The currency rocketed Monday after President Recep Tayyip Erdogan’s government said it planned a number of measures including the introduction of a program to protect savings from the lira’s fluctuations. The government will make up for losses incurred by holders of lira deposits should its declines against hard currencies exceed interest rates promised by banks, Erdogan sa